WO2010023874A1 - ロペラミド塩酸塩含有フィルム製剤 - Google Patents
ロペラミド塩酸塩含有フィルム製剤 Download PDFInfo
- Publication number
- WO2010023874A1 WO2010023874A1 PCT/JP2009/004087 JP2009004087W WO2010023874A1 WO 2010023874 A1 WO2010023874 A1 WO 2010023874A1 JP 2009004087 W JP2009004087 W JP 2009004087W WO 2010023874 A1 WO2010023874 A1 WO 2010023874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- film
- film preparation
- drug
- loperamide hydrochloride
- intermediate layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor
Definitions
- the present invention relates to a film preparation in which the bitter taste of loperamide hydrochloride is masked and a method for producing the same, and a method for masking the bitter taste of a film preparation containing loperamide hydrochloride.
- Loperamide hydrochloride is widely used as an antidiarrheal.
- Loperamide hydrochloride-containing preparations for example, preparations that can be taken even when sudden diarrhea is attacked in places where it is difficult to take water during commuting or during meetings are already on the market.
- loperamide hydrochloride has a very strong bitter taste and has a problem with its feeling of administration.
- Patent Documents 1 to 5 suggest that a sweetener, a surfactant, or the like is included together with a drug having bitterness.
- a sweetener, a surfactant, or the like is included together with a drug having bitterness.
- none of these known techniques suggests or teaches the bitterness masking of film formulations containing loperamide hydrochloride.
- Patent Document 6 As a method for masking the bitterness of a drug, it has been proposed to contain a drug having a bitter taste and 0.1 to 2.25% by weight of menthol in a mouth-dissolving or chewing type solid oral pharmaceutical composition.
- Patent Document 6 only tablets are substantially disclosed as dosage forms, and there is no suggestion or teaching about masking the bitterness of film formulations containing loperamide hydrochloride.
- An object of the present invention is to provide a film preparation in which the bitter taste of loperamide hydrochloride is masked.
- the present inventors surprisingly have a film in which a coating layer containing a specific component is laminated on both sides of a drug-containing layer containing loperamide hydrochloride and the specific component.
- a coating layer containing a specific component is laminated on both sides of a drug-containing layer containing loperamide hydrochloride and the specific component.
- a coating layer containing a film forming agent and a plasticizer (but not containing terpenes) is laminated on both sides of a drug-containing intermediate layer containing loperamide hydrochloride, terpenes and a film forming agent.
- the present invention provides a film preparation characterized by the above.
- the present invention is also a method for masking the bitter taste of a film preparation containing loperamide hydrochloride, A coating layer containing a film forming agent and a plasticizer (but not containing terpenes) is laminated on both sides of a drug-containing intermediate layer containing loperamide hydrochloride, terpenes and a film forming agent. A method is provided.
- the present invention is further a method for producing a film preparation containing loperamide hydrochloride masked with bitterness derived from loperamide hydrochloride, A coating layer containing a film forming agent and a plasticizer (but not containing terpenes) is laminated on both sides of a drug-containing intermediate layer containing loperamide hydrochloride, terpenes and a film forming agent.
- a manufacturing method is provided.
- the film preparation of the present invention Since the film preparation of the present invention has masked the bitter taste derived from loperamide hydrochloride, it can alleviate discomfort during taking. In addition, the film preparation of the present invention rapidly disintegrates and dissolves (fast-dissolving) only with moisture in the oral cavity, so that it has an immediate effect and is excellent in portability. Therefore, the excellent antipruritic action of loperamide hydrochloride is excellent in immediate relief of symptoms of diarrhea such as diarrhea caused by overeating or drinking, diarrhea caused by falling asleep, and diarrhea accompanied by abdominal pain.
- the film preparation of the present invention comprises a drug-containing intermediate layer containing loperamide hydrochloride and coating layers provided on both sides thereof.
- the drug-containing intermediate layer further contains terpenes and a film-forming agent
- the coating layer contains a film-forming agent and a plasticizer, and is free from terpenes.
- the dose of loperamide hydrochloride in the film preparation of the present invention can be appropriately set.
- the dose per adult is 0.5 to 2 mg
- the dose per day Is preferably 1 to 4 mg, more preferably 0.5 to 1 mg per dose, and more preferably 1 to 2 mg per day.
- it can be administered to an oral cavity once or several times per day for an adult, and the dose can be appropriately increased or decreased depending on age, weight and medical condition.
- the content of loperamide hydrochloride in the film preparation of the present invention is preferably 0.1 to 15% by mass, more preferably 0.5 to 10% by mass, and particularly preferably 1 to 5% by mass with respect to the entire film formulation.
- loperamide hydrochloride is preferably contained in the drug-containing intermediate layer in an amount of 1 to 5% by mass, particularly 2 to 4% by mass.
- terpenes is a concept including terpenes and essential oils containing terpenes.
- Specific examples of terpenes include limonene, pinene, camphene, cymen, cineole, citronellol, geraniol, nerol, linalool, menthol, terpiol, rosinol, borneol, isoborneol, menthone, camphor, eugenol, synzeanol, etc. it can. These include single stereoisomers and racemates.
- terpenes As essential oils containing terpenes, spruce oil, orange oil, mint oil, camphor white oil, eucalyptus oil, turpentine oil, lemon oil, pepper oil, clove oil, cinnamon oil, lavender oil, fennel oil, chamomile oil, Examples include perilla oil and spearmint oil. These terpenes may be used alone or in combination of two or more. In the present invention, menthol and mint oil are preferred as terpenes.
- the content of terpenes in the film preparation of the present invention is preferably 0.2 to 15% by mass, more preferably 0.5 to 10% by mass, and more preferably 1 to 5% by mass with respect to the entire film formulation. ⁇ 3% by weight is particularly preferred.
- the terpene is preferably contained in the drug-containing intermediate layer in an amount of 1 to 5% by mass, more preferably 2 to 4% by mass, and particularly preferably approximately the same amount as loperamide hydrochloride.
- the “film forming agent” means one having a property of forming a film when the aqueous solution is dried.
- the film forming agent is not particularly limited as long as it has such a film forming ability.
- hypromellose hydroxypropylmethylcellulose
- hydroxypropylcellulose pullulan
- hydroxyethylcellulose carboxymethylcellulose sodium
- carboxy Examples thereof include methylcellulose / calcium, carboxymethylcellulose / potassium, carboxymethylcellulose, polyvinylpyrrolidone and sodium alginate, and one or a combination of two or more selected from these is preferred.
- hypromellose, hydroxypropylcellulose, and the like are more preferable, and it is particularly preferable that hypromellose is contained in the coating layer and hydroxypropylcellulose is contained in the drug-containing intermediate layer.
- hypromellose means a mixed ether of cellulose methyl and hydroxypropyl, and can be produced by a known method.
- hypromellose commercially available products (for example, Shin-Etsu Chemical Co., Ltd., Dow Chemical Japan Co., Ltd., Matsumoto Yushi Seiyaku Co., Ltd., etc.) may be used.
- the substitution degree of the methoxy group and the hydroxypropoxy group in hypromellose is not particularly limited, and a desired substitution degree can be obtained by presetting the substitution degree when the cellulose is etherified.
- those containing 10 to 50%, more preferably 16.5 to 30%, especially 25 to 30% of methoxy groups are preferred, and 2 to 35%, more preferably 4 to 32%, particularly 4 to 32% of hydroxypropoxy groups.
- What contains 20% is preferable.
- particularly preferred is hypromellose containing 16.5 to 30% of methoxy group and 4 to 32% of hydroxypropoxy group.
- those containing 25 to 30% methoxy group and 4 to 20% hydroxypropoxy group are preferable.
- hypromellose 1828, hypromellose 2208, hypromellose 2906 and hypromellose 2910 are preferable.
- the viscosity of hypromellose is not particularly limited.
- it is preferable that the kinematic viscosity (15th revised Japanese Pharmacopoeia) of a 2% aqueous solution at 20 ° C. is about 6 mPa ⁇ s.
- hydroxypropylcellulose means hydroxypropyl ether of cellulose and can be produced by a known method. Moreover, you may use a commercial item (For example, Saneigen FFI Co., Ltd., Nippon Soda Co., Ltd., etc.) as hydroxypropyl cellulose.
- the degree of substitution in hydroxypropyl cellulose is not particularly limited, and a desired degree of substitution can be obtained by presetting the degree of substitution when etherifying cellulose. In the present invention, those containing 50 to 80%, more preferably 53.4 to 77.5% of a hydroxypropoxy group are preferable.
- the viscosity of hydroxypropyl cellulose is not particularly limited. For example, the viscosity of a 2% aqueous solution at 20 ° C. (15th revised Japanese Pharmacopoeia) is 2.0 to 2.9 mPa ⁇ s. preferable.
- the content of the film-forming agent in the film preparation of the present invention is preferably 40 to 95% by mass, more preferably 45 to 80% by mass, and particularly preferably 50 to 65% by mass with respect to the entire film formulation.
- the film forming agent is preferably contained in the coating layer in an amount of 68 to 80% by mass, particularly 70 to 75% by mass, and in the drug-containing intermediate layer, 40 to 50% by mass, particularly 45 to 50% by mass. % Content is preferable.
- the plasticizer means one having good compatibility with the film forming agent and imparting flexibility to the film forming agent.
- the plasticizer is not particularly limited as long as it is a material having such plasticity, and for example, glycerin, sesame oil, sorbitol, castor oil, propylene glycol, polyoxyethylene polyoxypropylene glycol, polysorbate 80 (poly Oxyethylene (20) sorbitan oleate), polyethylene glycol [for example, macrogol 400 (polymerization degree n of oxyethylene unit is 7 to 9, hereinafter the same), macrogol 600 (n is 11 to 13), macrogol 1500 (a mixture of equal amounts of n of 5 to 6 and n of 28 to 36), macrogol 4000 (n is 59 to 84), macrogol 6000 (n is 165 to 210)] and the like.
- the plasticizer one or a combination of two or more selected from these is preferable. Among these, glycerin, propylene glycol, and macrogol 400 are more preferable.
- the content of the plasticizer is preferably 1 to 20% by mass, more preferably 3 to 15% by mass, and particularly preferably 5 to 10% by mass with respect to the entire film preparation.
- the plasticizer is preferably contained in the coating layer and the drug-containing intermediate layer in an amount of 5 to 10% by mass, particularly 7 to 10% by mass.
- the film preparation of the present invention contains drugs such as antacids, stomachic agents, digestives, intestinals, antipruritics other than loperamide hydrochloride, analgesics and antispasmodics, vitamins, amino acids, and other herbal medicines. It is possible to mix
- Examples of the antacid include dry aluminum hydroxide gel, magnesium aluminate silicate, magnesium aluminate metasilicate, aluminum silicate, hydrotalcite, magnesium magnesium hydroxide, aluminum hydroxide gel, aluminum hydroxide / hydrogen carbonate Sodium coprecipitation product, aluminum hydroxide / magnesium carbonate mixed dry gel, aluminum hydroxide / calcium carbonate / magnesium carbonate coprecipitation product, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium silicate, magnesium hydroxide Co-precipitation product of potassium aluminum sulfate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, calcium lactate, calcium hydroxide, sodium hydrogen carbonate, sodium citrate, sodium acetate
- Anion exchange resin such as polyaminomethylene resin, H2 receptor antagonists such as famotidine, ranitidine and cimetidine, pirenzepine hydrochloride, proton pump inhibitor, gastric mucin, bandit bone, stone decision, oyster, amino
- stomachic agents include, for example, aniseed fruit, aloe, musk, depressant, glaze, life-grass, yellow rice, jaundice, yellow chain, processed oak, gadget, kakko, kina, homika, shokyo, columnus root, psoriasis , Rice husk, coconut, cinnamon, gentian, kojin, kobok, wuluo, cucumber, colombo, kondurango, yam, yamana, shisoko, sand, ginger, shrimp, green skin, stone root, centaurium grass, sea bream, coral, Soha, Daigoka, Daihuang, bamboo Ginseng, Clove, Chen, Chilli, Spruce, Animal Gall, Nigaki, Nikuzuku, Ginseng, Light Pack, Hihatsu, White Birch, Hop, Homika Extract, Sleeping Leaves, Mika, Michichi, Ryobi, Examples include herbal medicines such as bean paste, koji, betaine
- Examples of the digestive agent include diastase, pancreatin, pepsin, ptyalin, ⁇ -galactosidase, amylase, trypsin, papain, protease, lipase, cellulase, mamitase, samprose, newase, prozyme, molsin, panprosin, biotamirase, hirotase, urso
- Examples include deoxycholic acid, oxycolanic acids, cholic acid, bile powder, bile extract, dehydrocholic acid, animal bile and the like.
- intestinal regulating agent examples include live intestinal fungi components, red buds, asenyaku, bai, tsutsumeishi, genokosho and the like.
- Antidiarrheal agents other than loperamide hydrochloride include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth subsalicylate, bismuth nitrate, bismuth carbonate, bismuth sub gallate, tannin Acid, albumin tannate, methylene thymol tannin, kaolin, natural aluminum silicate, hydroxy hydroxynaphthoate, pectin, medicinal charcoal, precipitated calcium carbonate, calcium lactate, calcium hydrogen phosphate, asenyaku, sea buckthorn, buckwheat, auren, kudin, genko , Pentaploids, hawt
- analgesic and antispasmodic agents examples include papaverine hydrochloride, ethyl aminobenzoate, scopolamine hydrobromide, methyl scopolamine bromide, yanko cord, licorice, magnolia, glaze, thimepidium bromide, oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride , Methyl atropine bromide, methyl l-hyostiamine bromide, methylbenactidium bromide, belladonna extract, funnel extract, diphenylpiperidinomethyldioxolane iodide, funnel root total alkanoid citrate, isopropamide iodide, odor And methyl anisotropin bromide, butyl scopolamine bromide, thixidium bromide, oxesasein, engosac, licorice, kokuboku
- vitamins include vitamins A such as retinal, retinol, retinoic acid, carotene, dehydroretinal, lycopene and their pharmacologically acceptable salts; thiamine, thiamine disulfide, dicetiamine, octotiamine, chicotiamine, bis Ibuthiamine, bisbenchamine, prosultiamine, benfotiamine, fursultiamine, riboflavin, flavin adenine dinucleotide, pyridoxine, pyridoxal, hydroxocobalamin, cyanocobalamin, methylcobalamin, deoxyadenocobalamin, folic acid, tetrahydrofolic acid, dihydrofolic acid, Nicotinic acid, nicotinic amide, nicotinic alcohol, pantothenic acid, panthenol, biotin, choline, inositol and their pharmacologically acceptable Vitamin B
- amino acids examples include leucine, isoleucine, valine, methionine, threonine, alanine, phenylalanine, tryptophan, lysine, asparagine, aspartic acid, serine, glutamine, glutamic acid, proline, tyrosine, cysteine, histidine, ornithine, hydroxyproline, hydroxylysine.
- herbal medicines include, for example, carrots, yokuinin, chamomile, keihi, kakachi, mao, nantenjitsu, ohhi, onji, licorice, kyounin, shazenji, zensen, sexan, senega, tokon, baimo, asenyaku, fennel, ogon, caronine , Keihi, Gooh, Gomin, Saishin, Zion, Musk, Shajin, Shoyo, Sakuhakuhi, Soyo, Chikutsujinjin, Chimpi, Carrot, Bakumondou, Hange, Akamegashiwa and the like.
- one or more commonly used pharmaceutical additives may be used as necessary.
- the pharmaceutical additive include, but are not limited to, a disintegrant, an excipient, a poorly water-soluble polymer substance, a coloring agent, an antioxidant, a corrigent, and a flavoring agent.
- disintegrants include carmellose and salts thereof, starch, sucrose fatty acid ester, gelatin, sodium bicarbonate, dextrin, dehydroacetic acid and salts thereof, povidone, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene polyoxypropylene glycol. Etc.
- excipients include titanium oxide, magnesium hydroxide alumina, magnesium hydroxide, aluminum silicate, silicon dioxide, anhydrous sodium sulfate, anhydrous calcium hydrogen phosphate, sodium chloride, hydrous amorphous silicon oxide, and aluminate silicate.
- Examples of the poorly water-soluble polymer substance include ethyl cellulose, hydroxypropyl methyl cellulose phthalate, methyl cellulose, polyvinyl alcohol, carboxy vinyl polymer and the like.
- Examples of the colorant include yellow iron sesquioxide, brown iron oxide, caramel, black iron oxide, titanium oxide, iron sesquioxide, tar dye, aluminum lake dye, copper chlorophyllin sodium, and the like.
- Examples of flavoring agents include orange flavor, grapefruit flavor, strawberry flavor, lemon flavor and the like.
- antioxidant examples include ascorbic acid, sodium bisulfite, sodium sulfite, sodium edetate, erythorbic acid, tocopherol acetate, dibutylhydroxytoluene, natural vitamin E, tocopherol, butylhydroxyanisole and the like.
- corrigent examples include acidulants such as ascorbic acid, tartaric acid, citric acid, malic acid and salts thereof, and sweeteners such as aspartame, stevia, sucralose, glycyrrhizic acid, thaumatin, acesulfame potassium, saccharin, and saccharin sodium. Can be mentioned.
- the disintegrant is preferably added in an amount of 1 to 8% by mass, particularly 2 to 6% by mass, based on the entire film preparation.
- the disintegrant is added to the coating layer in an amount of 5 to 20% by mass, particularly 7 to 15% by mass.
- the excipient is preferably added in an amount of 15 to 60% by mass, particularly 15 to 30% by mass, based on the entire film preparation.
- the excipient is added in an amount of 5 to 20% by mass, particularly 7 to 15% by mass, and 10 to 40% by mass, particularly 25 to 35% by mass, in the drug-containing intermediate layer. It is.
- the poorly water-soluble polymer substance can be added in an amount of preferably 1 to 10% by mass with respect to the entire film preparation.
- the colorant can be added preferably in the range of 0.05 to 10% by mass with respect to the entire film preparation.
- the antioxidant can be added preferably in the range of 0.1 to 5% by mass relative to the whole film preparation.
- the corrigent can be added preferably in the range of 1 to 10% by mass with respect to the whole film preparation.
- the flavoring agent can be added preferably in the range of 0.01 to 0.1% by mass with respect to the entire film preparation.
- the film preparation of the present invention has a three-layer structure in which a coating layer, a drug-containing intermediate layer, and a coating layer are sequentially laminated.
- layers of the same type are stacked adjacent to each other, they are in close contact with each other and perform the same function, and therefore are treated as substantially one layer in the present invention.
- the thickness of the entire film preparation is preferably 30 to 300 ⁇ m, particularly preferably 30 to 200 ⁇ m.
- the thickness of the coating layer is preferably 5 to 100 ⁇ m, particularly preferably 10 to 50 ⁇ m
- the thickness of the drug-containing intermediate layer is preferably 10 to 200 ⁇ m, particularly preferably 10 to 100 ⁇ m.
- the size of the film preparation of the present invention is not particularly limited as long as it is easy to take, but for example, it is preferably about 0.5 to 10 cm 2 .
- the shape is not particularly limited as long as it is easy to take, and for example, a square, a circle, an ellipse or the like can be appropriately selected.
- a functional layer may be provided between the drug-containing intermediate layer and the coating layer as long as the object of the present invention is not impaired.
- a support layer for improving handling properties mainly composed of hydroxypropylmethylcellulose or a moisture-proof layer mainly composed of ethylcellulose for moisture-proofing is exemplified.
- the thickness of each layer can be appropriately set within a range that does not impair the object of the present invention.
- the film preparation of the present invention can be appropriately prepared by conventional or known methods. For example, by laminating a first coating layer on a release film such as PET (polyethylene terephthalate), and then laminating a drug-containing intermediate layer, by laminating a second coating layer on the intermediate layer, Can be prepared. In addition, an intermediate product in which a first coating layer is laminated on a release film, and further a drug intermediate layer is laminated, and an intermediate product in which a second coating layer is further laminated on the release film and a drug intermediate layer is further laminated. It can also be prepared by preparing a product, and then laminating and pressing so that both drug intermediate layers face each other. In addition, the film forming agent in a 1st coating layer and a 2nd coating layer may be the same, and may differ.
- Example 1 50 g of powdered reduced maltose water candy and 40 g of Macrogol 400 were dissolved in 500 g of water. Next, a solution in which 50 g of titanium oxide was dispersed in 750 g of absolute ethanol was added to this solution. Then, 360 g of hypromellose was added to the obtained liquid to obtain a coating layer preparation liquid. In a mixed solution of 810 g of water and 810 g of absolute ethanol, 27 g of loperamide hydrochloride, 64.8 g of Macrogol 400, 256.5 g of powdered reduced maltose water candy, 54 g of sodium saccharin and 27 g of 1-menthol were dissolved.
- hydroxypropyl cellulose and 1.35 g of a flavoring agent were added to obtain a drug-containing intermediate layer preparation solution.
- the coating layer preparation solution was uniformly applied on the PET film, and then dried with warm air to form a coating layer having a mass of 5 mg per area of 2.72 cm 2 .
- the drug-containing intermediate layer preparation solution is uniformly applied above the coating layer, it is dried with warm air to form a drug-containing intermediate layer having a mass per area of 2.72 cm 2 of 7.5125 mg, thereby obtaining intermediate product 1 It was.
- Two intermediate products 1 are produced, and bonded and pressure-bonded so that the drug-containing intermediate layers face each other, and an intermediate product 2 in which a coating layer, a drug-containing intermediate layer, and a coating layer are sequentially laminated between two PET films is obtained. It was.
- One PET film of the intermediate product 2 was peeled off and cut into an area of 2.72 cm 2 , and the other PET film was peeled off to obtain a film preparation according to the present invention.
- the drug-containing intermediate layer preparation solution is uniformly applied above the coating layer, it is dried with warm air to form a drug-containing intermediate layer having a mass per area of 2.72 cm 2 of 7.5125 mg, thereby obtaining an intermediate product a.
- Two intermediate products a are prepared, and bonded and pressure-bonded so that the drug-containing intermediate layers are opposed to each other, thereby obtaining an intermediate product b in which a coating layer, a drug-containing intermediate layer, and a coating layer are sequentially laminated between two PET films. It was.
- One PET film of the intermediate product b was peeled off and cut into an area of 2.72 cm 2 , and the other PET film was peeled off to obtain a film preparation.
- the drug-containing intermediate layer preparation solution After the drug-containing intermediate layer preparation solution is uniformly applied above the coating layer, it is dried with warm air to form a drug-containing intermediate layer having a mass per area of 2.72 cm 2 of 7.5125 mg, thereby obtaining an intermediate product c. It was. Two intermediate products c are prepared and bonded and pressure-bonded so that the drug-containing intermediate layers face each other, and an intermediate product d is obtained in which a coating layer, a drug-containing intermediate layer, and a coating layer are sequentially laminated between two PET films. It was. One PET film of the intermediate product d was peeled off and cut into an area of 2.72 cm 2 , and the other PET film was peeled off to obtain a film preparation.
- the film preparation of the present invention in the form of sandwiching a drug-containing intermediate layer containing loperamide hydrochloride having strong bitterness together with menthol in a coating layer not containing menthol is loperamide. It was confirmed that an unpleasant taste of hydrochloride can be masked and a film preparation easy to take can be obtained.
- the film preparation of Comparative Example 1 in which a drug-containing intermediate layer containing loperamide hydrochloride and not containing menthol is sandwiched between coating layers containing menthol cannot mask the unpleasant taste of loperamide hydrochloride It was.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
ロペラミド塩酸塩、テルペン類及びフィルム形成剤を含有する薬物含有中間層の両面に、フィルム形成剤及び可塑剤を含有するコーティング層(但し、テルペン類は含有しない)を積層させることを特徴とする、方法を提供するものである。
ロペラミド塩酸塩、テルペン類及びフィルム形成剤を含有する薬物含有中間層の両面に、フィルム形成剤及び可塑剤を含有するコーティング層(但し、テルペン類は含有しない)を積層させることを特徴とする、製造方法を提供するものである。
本発明のフィルム製剤におけるロペラミド塩酸塩の投与量は適宜設定することが可能であるが、例えば、成人に対して1回当たりの服用量が0.5~2mgであり、かつ1日当たりの服用量が1~4mgであることが好ましく、1回当たりの服用量が0.5~1mgであり、かつ1日当たりの服用量が1~2mgであることがより好ましい。このように、成人に対して1日当たり1回~数回に分けて口腔内に投与することが可能であり、また年齢、体重、病状により投与量を適宜増減することもできる。
本発明のフィルム製剤におけるロペラミド塩酸塩の含有量は、フィルム製剤全体に対して0.1~15質量%が好ましく、0.5~10質量%が更に好ましく、1~5質量%が特に好ましい。特に好ましい態様として、ロペラミド塩酸塩は、薬物含有中間層中に1~5質量%、特に2~4質量%含有させることが好ましい。
本発明においては、テルペン類として、メントール及びハッカ油が好ましい。
可塑剤の含有量は、フィルム製剤全体に対して1~20質量%が好ましく、3~15質量%が更に好ましく、5~10質量%が特に好ましい。特に好ましい態様として、可塑剤は、コーティング層及び薬物含有中間層中に、5~10質量%、特に7~10質量%それぞれ含有させることが好ましい。
ロペラミド塩酸塩以外の止瀉剤としては、例えば、アクリノール、塩化ベルベリン、グアヤコール、クレオソート、サリチル酸フェニル、炭酸グアヤコール、タンニン酸ベルベリン、次サリチル酸ビスマス、次硝酸ビスマス、次炭酸ビスマス、次没食子酸ビスマス、タンニン酸、タンニン酸アルブミン、メチレンチモールタンニン、カオリン、天然ケイ酸アルミニウム、ヒドロキシナフトエ酸アルミニウム、ペクチン、薬用炭、沈降炭酸カルシウム、乳酸カルシウム、リン酸水素カルシウム、アセンヤク、ウバイ、オウバク、オウレン、クジン、ゲンノショウコ、五倍子、サンザシ、センブリ、ヨウバイヒ等が挙げられる。
他の生薬としては、例えば、ニンジン、ヨクイニン、カミツレ、ケイヒ、葛根湯、マオウ、ナンテンジツ、オウヒ、オンジ、カンゾウ、キョウニン、シャゼンジ、シャゼンソウ、セキサン、セネガ、トコン、バイモ、アセンヤク、ウイキョウ、オウゴン、カロニン、ケイヒ、ゴオウ、ゴミン、サイシン、シオン、ジャコウ、シャジン、ショウキョウ、ソウハクヒ、ソヨウ、チクセツニンジン、チンピ、ニンジン、バクモンドウ、ハンゲ、アカメガシワ等が挙げられる。
着色剤としては、例えば、黄色三二酸化鉄、褐色酸化鉄、カラメル、黒酸化鉄、酸化チタン、三二酸化鉄、タール色素、アルミニウムレーキ色素、銅クロロフィリンナトリウム等が挙げられる。
着香剤としては、例えば、オレンジフレーバー、グレープフルーツフレーバー、ストロベリーフレーバー、レモンフレーバー等が挙げられる。
矯味剤としては、例えば、アスコルビン酸、酒石酸、クエン酸、リンゴ酸及びこれらの塩等の酸味剤や、アスパルテーム、ステビア、スクラロース、グリチルリチン酸、ソーマチン、アセスルファムカリウム、サッカリン、サッカリンナトリウム等の甘味剤等が挙げられる。
賦形剤は、フィルム製剤全体に対して15~60質量%、特に15~30質量%添加することが好ましい。特に好ましい態様としては、賦形剤をコーティング層中に5~20質量%、特に7~15質量%添加し、薬物含有中間層中に10~40質量%、特に25~35質量%添加することである。
難水溶性高分子物質は、フィルム製剤全体に対して好ましくは1~10質量%の範囲で添加することができる。着色剤は、フィルム製剤全体に対して好ましくは0.05~10質量%の範囲で添加することができる。抗酸化剤は、フィルム製剤全体に対して好ましくは0.1~5質量%の範囲で添加することができる。矯味剤は、フィルム製剤全体に対して好ましくは1~10質量%の範囲で添加することができる。着香剤は、フィルム製剤全体に対して好ましくは0.01~0.1質量%の範囲で添加することができる。
水500gに粉末還元麦芽糖水アメ50g及びマクロゴール400 40gを溶解した。次いで、この液に、無水エタノール750gに酸化チタン50gを分散した液を加えた。そして、得られた液にヒプロメロース360gを加えてコーティング層調製液を得た。
水810g及び無水エタノール810gの混液にロペラミド塩酸塩27g、マクロゴール400 64.8g、粉末還元麦芽糖水アメ256.5g、サッカリンナトリウム54g及びl-メントール27gを溶解した。この液にヒドロキシプロピルセルロース380.7g及び着香剤1.35gを加えて薬物含有中間層調製液を得た。
PETフィルム上にコーティング層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が5mgのコーティング層を形成した。コーティング層の上方に薬物含有中間層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が7.5125mgの薬物含有中間層を形成し、中間製品1を得た。
中間製品1を2式作製し、薬物含有中間層同士が対向するように張り合わせ圧着し、2つのPETフィルム間に、コーティング層、薬物含有中間層、コーティング層が順次積層された中間製品2を得た。
中間製品2の一方のPETフィルムを剥離し、面積2.72cm2に裁断し、他方のPETフィルムを剥離して、本発明にかかるフィルム製剤を得た。
水500gに粉末還元麦芽糖水アメ50g及びマクロゴール400 40gを溶解した。次いで、この液に、無水エタノール250gにl-メントール25gを溶解した液及び無水エタノール500gに酸化チタン50gを分散した液を加えた。そして、得られた液にヒプロメロース335gを加えてコーティング層調製液を得た。
水810g及び無水エタノール810gの混液にロペラミド塩酸塩27g、マクロゴール400 64.8g、粉末還元麦芽糖水アメ256.5g及びサッカリンナトリウム54gを溶解した。この液にヒドロキシプロピルセルロース407.7g及び着香剤1.35gを加えて薬物含有中間層調製液を得た。
PETフィルム上にコーティング層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が5mgのコーティング層を形成した。コーティング層の上方に薬物含有中間層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が7.5125mgの薬物含有中間層を形成し、中間製品aを得た。
中間製品aを2式作製し、薬物含有中間層同士が対向するように張り合わせ圧着し、2つのPETフィルム間に、コーティング層、薬物含有中間層、コーティング層が順次積層された中間製品bを得た。
中間製品bの一方のPETフィルムを剥離し、面積2.72cm2に裁断し、他方のPETフィルムを剥離して、フィルム製剤を得た。
水500gに粉末還元麦芽糖水アメ50g及びマクロゴール400 40gを溶解した。次いで、この液に、無水エタノール250gにl-メントール25gを溶解した液及び無水エタノール500gに酸化チタン50gを分散した液を加えた。そして、得られた液にヒプロメロース335gを加えてコーティング層調製液を得た。
水810g及び無水エタノール810gの混液にロペラミド塩酸塩27g、マクロゴール400 64.8g、粉末還元麦芽糖水アメ256.5g、サッカリンナトリウム54g及びl-メントール27gを溶解した。この液にヒドロキシプロピルセルロース380.7g及び着香剤1.35gを加えて薬物含有中間層調製液を得た。
PETフィルム上にコーティング層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が5mgのコーティング層を形成した。コーティング層の上方に薬物含有中間層調製液を均一に塗布した後、温風にて乾燥し面積2.72cm2当たりの質量が7.5125mgの薬物含有中間層を形成し、中間製品cを得た。
中間製品cを2式作製し、薬物含有中間層同士が対向するように張り合わせ圧着し、2つのPETフィルム間に、コーティング層、薬物含有中間層、コーティング層が順次積層された中間製品dを得た。
中間製品dの一方のPETフィルムを剥離し、面積2.72cm2に裁断し、他方のPETフィルムを剥離して、フィルム製剤を得た。
実施例1、比較例1及び比較例2で得られたフィルム製剤の服用感を評価した。フィルム製剤の評価は6名のパネラーにより服用感(苦味)について官能試験を実施した。評価基準は、「苦味がほとんど気にならない」を2点とし、「苦味がやや気になる」を1点とし、「苦味が気になり、不味である」を0点とした。したがって、合計点数の値が大きいほど、苦味がマスキングされていることを意味する。その合計点数を、各フィルム製剤の組成とともに表1に示した。
一方、ロペラミド塩酸塩を含み、かつメントールを含まない薬物含有中間層を、メントールを含有するコーティング層で挟み込んだ比較例1のフィルム製剤は、ロペラミド塩酸塩の不快な味をマスキングすることができなかった。また、ロペラミド塩酸塩とメントールを含有する薬物含有中間層を、メントールを含有するコーティング層で挟み込んだ比較例2のフィルム製剤も、ロペラミド塩酸塩の不快な味をマスキングすることができなかった。
したがって、ロペラミド塩酸塩の不快な味のマスキングは、単にメントールを配合することだけでは達成することができず、メントールを薬物含有中間層のみに配合することにより、不快な味のマスキングが達成されることが判明した。
また、本発明のフィルム製剤(実施例1)を水なしで服用させたところ、30秒以内に口腔内で溶解したことから、即効性が期待されることが確認された。
Claims (7)
- ロペラミド塩酸塩、テルペン類及びフィルム形成剤を含有する薬物含有中間層の両面に、フィルム形成剤及び可塑剤を含有するコーティング層(但し、テルペン類は含有しない)が積層されていることを特徴とするフィルム製剤。
- テルペン類がメントールである、請求項1に記載のフィルム製剤。
- フィルム形成剤がヒドロキシプロピルセルロース及び/又はヒプロメロースである、請求項1又は2に記載のフィルム製剤。
- 口腔内溶解型である、請求項1~3いずれか1項に記載のフィルム製剤。
- ロペラミド塩酸塩由来の苦味をマスキングしたものである、請求項1~4いずれか1項に記載のフィルム製剤。
- ロペラミド塩酸塩を含有するフィルム製剤の苦味のマスキング方法であって、
ロペラミド塩酸塩、テルペン類及びフィルム形成剤を含有する薬物含有中間層の両面に、フィルム形成剤及び可塑剤を含有するコーティング層(但し、テルペン類は含有しない)を積層させることを特徴とする、方法。 - ロペラミド塩酸塩由来の苦味をマスキングしたロペラミド塩酸塩を含有するフィルム製剤の製造方法であって、
ロペラミド塩酸塩、テルペン類及びフィルム形成剤を含有する薬物含有中間層の両面に、フィルム形成剤及び可塑剤を含有するコーティング層(但し、テルペン類は含有しない)を積層させることを特徴とする、製造方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09809530.0A EP2324833B1 (en) | 2008-08-25 | 2009-08-25 | Film preparation containing loperamide hydrochloride |
CN200980133412.XA CN102131507B (zh) | 2008-08-25 | 2009-08-25 | 含有盐酸洛哌丁胺的膜制剂 |
US13/060,707 US20110159058A1 (en) | 2008-08-25 | 2009-08-25 | Film preparation containing loperamide hydrochloride |
AU2009285467A AU2009285467B2 (en) | 2008-08-25 | 2009-08-25 | Film preparation containing loperamide hydrochloride |
JP2010526532A JP5624472B2 (ja) | 2008-08-25 | 2009-08-25 | ロペラミド塩酸塩含有フィルム製剤 |
KR1020117004525A KR101866189B1 (ko) | 2008-08-25 | 2009-08-25 | 로페라마이드 염산염 함유 필름 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008214839 | 2008-08-25 | ||
JP2008-214839 | 2008-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010023874A1 true WO2010023874A1 (ja) | 2010-03-04 |
Family
ID=41721057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/004087 WO2010023874A1 (ja) | 2008-08-25 | 2009-08-25 | ロペラミド塩酸塩含有フィルム製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20110159058A1 (ja) |
EP (1) | EP2324833B1 (ja) |
JP (1) | JP5624472B2 (ja) |
KR (1) | KR101866189B1 (ja) |
CN (1) | CN102131507B (ja) |
AU (1) | AU2009285467B2 (ja) |
MY (1) | MY163111A (ja) |
TW (1) | TWI513478B (ja) |
WO (1) | WO2010023874A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009007310A (ja) * | 2007-06-29 | 2009-01-15 | Lintec Corp | フィルム状製剤およびその製造方法 |
WO2011108643A1 (ja) * | 2010-03-03 | 2011-09-09 | 救急薬品工業株式会社 | 不快な味を有する薬物を含有するフィルム製剤 |
EP2557944A1 (en) * | 2010-04-15 | 2013-02-20 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
US20130243870A1 (en) * | 2010-12-03 | 2013-09-19 | Nippon Soda Co., Ltd. | Hydroxyalkyl cellulose |
US9706790B2 (en) | 2011-10-20 | 2017-07-18 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101318059B1 (ko) * | 2011-07-01 | 2013-10-15 | 광동제약 주식회사 | 로페라마이드와 베타-시클로덱스트린 포접물을 함유하는 가식성 필름제제 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117149A (ja) | 1991-06-12 | 1993-05-14 | Ota Seiyaku Kk | 医薬製剤 |
JPH0930969A (ja) | 1995-05-18 | 1997-02-04 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
JPH09323931A (ja) | 1996-06-04 | 1997-12-16 | Taisho Pharmaceut Co Ltd | 塩酸ロペラミド配合液剤組成物 |
JPH10101582A (ja) | 1996-09-30 | 1998-04-21 | Taisho Pharmaceut Co Ltd | 口腔内溶解型固形剤 |
JPH1135450A (ja) | 1997-07-21 | 1999-02-09 | Lab Prographarm | 迅速に分解する改良多粒子錠剤 |
JP2000095707A (ja) | 1998-09-22 | 2000-04-04 | Rohto Pharmaceut Co Ltd | 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物 |
JP2002525306A (ja) * | 1998-09-25 | 2002-08-13 | ワーナー−ランバート・カンパニー | 急速溶解性口内消耗性フィルム |
JP2003527410A (ja) * | 2000-03-23 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 味遮蔽剤としてのイオン交換樹脂を含有する急速溶解性で経口的に消尽されうるフィルム |
JP2005232072A (ja) * | 2004-02-19 | 2005-09-02 | Sato Pharmaceutical Co Ltd | 高湿度及び低湿度下で安定なフィルム製剤及びフィルム食品 |
JP2005263704A (ja) * | 2004-03-19 | 2005-09-29 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
JP2005289867A (ja) * | 2004-03-31 | 2005-10-20 | Lintec Corp | 経口投与剤 |
JP2007254340A (ja) * | 2006-03-22 | 2007-10-04 | Lintec Corp | 経口投与剤 |
JP2008517935A (ja) * | 2004-10-21 | 2008-05-29 | ノバルティス アクチエンゲゼルシャフト | ジクロフェナクを含む医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050422A1 (en) * | 2001-10-12 | 2008-02-28 | Monosolrx, Llc. | Method of administering a film product containing a drug |
WO2003030882A1 (en) * | 2001-10-12 | 2003-04-17 | Kosmos Pharma | Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform |
DE10207394B4 (de) * | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte oblatenförmige Arzneizubereitung |
AU2003235294B2 (en) * | 2002-05-16 | 2008-04-17 | Kyukyu Pharmaceutical Co., Ltd. | Quickly soluble film preparations |
US20070166336A1 (en) * | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
-
2009
- 2009-08-25 MY MYPI2011000786A patent/MY163111A/en unknown
- 2009-08-25 TW TW098128546A patent/TWI513478B/zh active
- 2009-08-25 WO PCT/JP2009/004087 patent/WO2010023874A1/ja active Application Filing
- 2009-08-25 EP EP09809530.0A patent/EP2324833B1/en active Active
- 2009-08-25 US US13/060,707 patent/US20110159058A1/en not_active Abandoned
- 2009-08-25 AU AU2009285467A patent/AU2009285467B2/en not_active Ceased
- 2009-08-25 JP JP2010526532A patent/JP5624472B2/ja active Active
- 2009-08-25 CN CN200980133412.XA patent/CN102131507B/zh active Active
- 2009-08-25 KR KR1020117004525A patent/KR101866189B1/ko active IP Right Grant
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117149A (ja) | 1991-06-12 | 1993-05-14 | Ota Seiyaku Kk | 医薬製剤 |
JPH0930969A (ja) | 1995-05-18 | 1997-02-04 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
JPH09323931A (ja) | 1996-06-04 | 1997-12-16 | Taisho Pharmaceut Co Ltd | 塩酸ロペラミド配合液剤組成物 |
JPH10101582A (ja) | 1996-09-30 | 1998-04-21 | Taisho Pharmaceut Co Ltd | 口腔内溶解型固形剤 |
JPH1135450A (ja) | 1997-07-21 | 1999-02-09 | Lab Prographarm | 迅速に分解する改良多粒子錠剤 |
JP2000095707A (ja) | 1998-09-22 | 2000-04-04 | Rohto Pharmaceut Co Ltd | 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物 |
JP2002525306A (ja) * | 1998-09-25 | 2002-08-13 | ワーナー−ランバート・カンパニー | 急速溶解性口内消耗性フィルム |
JP2003527410A (ja) * | 2000-03-23 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 味遮蔽剤としてのイオン交換樹脂を含有する急速溶解性で経口的に消尽されうるフィルム |
JP2005232072A (ja) * | 2004-02-19 | 2005-09-02 | Sato Pharmaceutical Co Ltd | 高湿度及び低湿度下で安定なフィルム製剤及びフィルム食品 |
JP2005263704A (ja) * | 2004-03-19 | 2005-09-29 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
JP2005289867A (ja) * | 2004-03-31 | 2005-10-20 | Lintec Corp | 経口投与剤 |
JP2008517935A (ja) * | 2004-10-21 | 2008-05-29 | ノバルティス アクチエンゲゼルシャフト | ジクロフェナクを含む医薬組成物 |
JP2007254340A (ja) * | 2006-03-22 | 2007-10-04 | Lintec Corp | 経口投与剤 |
Non-Patent Citations (2)
Title |
---|
See also references of EP2324833A4 * |
YASUHIKO NAKAMURA: "Nigami no Masking to Joho Seizai", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN, vol. 65, no. 3, 2005, pages 159 - 164, XP008142946 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009007310A (ja) * | 2007-06-29 | 2009-01-15 | Lintec Corp | フィルム状製剤およびその製造方法 |
WO2011108643A1 (ja) * | 2010-03-03 | 2011-09-09 | 救急薬品工業株式会社 | 不快な味を有する薬物を含有するフィルム製剤 |
JP5781062B2 (ja) * | 2010-03-03 | 2015-09-16 | 救急薬品工業株式会社 | 不快な味を有する薬物を含有するフィルム製剤 |
US8865779B2 (en) | 2010-04-15 | 2014-10-21 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
EP2557944A4 (en) * | 2010-04-15 | 2014-06-11 | Chromocell Corp | COMPOUNDS, COMPOSITIONS, AND METHODS OF REDUCING OR ELIMINATING AMERTUME |
CN103037710A (zh) * | 2010-04-15 | 2013-04-10 | 卓莫赛尔公司 | 用于减小或消除苦味的化合物、组合物和方法 |
EP2557944A1 (en) * | 2010-04-15 | 2013-02-20 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
US9408407B2 (en) | 2010-04-15 | 2016-08-09 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
RU2596989C2 (ru) * | 2010-04-15 | 2016-09-10 | Крафт Фудс Груп Брэндс Ллс | Соединения, композиции и способы для снижения или устранения горького вкуса |
US9872514B2 (en) | 2010-04-15 | 2018-01-23 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
US20130243870A1 (en) * | 2010-12-03 | 2013-09-19 | Nippon Soda Co., Ltd. | Hydroxyalkyl cellulose |
JP5995284B2 (ja) * | 2010-12-03 | 2016-09-21 | 日本曹達株式会社 | 固形製剤 |
US9706790B2 (en) | 2011-10-20 | 2017-07-18 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
Also Published As
Publication number | Publication date |
---|---|
MY163111A (en) | 2017-08-15 |
AU2009285467A1 (en) | 2010-03-04 |
US20110159058A1 (en) | 2011-06-30 |
JPWO2010023874A1 (ja) | 2012-01-26 |
EP2324833A4 (en) | 2012-10-10 |
JP5624472B2 (ja) | 2014-11-12 |
AU2009285467B2 (en) | 2014-09-18 |
TW201012487A (en) | 2010-04-01 |
TWI513478B (zh) | 2015-12-21 |
EP2324833B1 (en) | 2017-07-19 |
CN102131507A (zh) | 2011-07-20 |
KR20110044763A (ko) | 2011-04-29 |
KR101866189B1 (ko) | 2018-06-11 |
CN102131507B (zh) | 2015-06-10 |
EP2324833A1 (en) | 2011-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2543366B1 (en) | Film preparation containing medicament with unpleasant taste | |
EP3027172B1 (en) | Oral dispersible films | |
JP5624472B2 (ja) | ロペラミド塩酸塩含有フィルム製剤 | |
JP5259880B2 (ja) | 経口剤 | |
JP2013515782A (ja) | オンダンセトロンを含む経口投与可能なフィルム製剤 | |
US20170182105A1 (en) | Orodispersible film | |
JP6088151B2 (ja) | 医薬組成物 | |
CN111065384A (zh) | 扑热息痛的口腔崩解膜组合物 | |
JP5284070B2 (ja) | 口腔内粘膜貼付製剤 | |
TWI612978B (zh) | 口溶膜 | |
KR20200131913A (ko) | 플루르비프로펜을 포함하는 약학적 조성물 | |
JP2012031164A (ja) | フィルム状製剤 | |
US20100216876A1 (en) | Antidiarrhetic composition, product containing the same and method of preventing diahhrea | |
JP2007145731A (ja) | 止瀉効果を有する内服用製剤 | |
JP7451124B2 (ja) | 内服組成物およびその吸湿抑制方法 | |
JP2005162713A (ja) | 内服用組成物 | |
JP2011068614A (ja) | ビタミン製剤 | |
TW202412752A (zh) | 固體製劑及其製造方法 | |
Pasha | Formulation and Evaluation of Orodispersible Fast Release Films of Non Sedative Long Acting H-1 Anti-Histamine Loratadine | |
JP2005330245A (ja) | 鼻炎用薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980133412.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09809530 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010526532 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2009809530 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009809530 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009285467 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1343/DELNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117004525 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009285467 Country of ref document: AU Date of ref document: 20090825 Kind code of ref document: A |